CSPC Pharma climbs as mpox mRNA vaccine gets US FDA clinical trial approval
11/08/2026 05:32
BUZZ-CSPC Pharma climbs as mpox mRNA vaccine gets US FDA clinical trial approval ** Shares of CSPC Pharmaceutical Group 1093.HK climb 3.3% to HK$8.91, on course for their biggest .one-day pct gain since July 20
** The Chinese drug manufacturer says its co-developed SYS6037 injection, or mpox mRNA vaccine, has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.
** The product is a multi-antigen mpox vaccine encoded by a single mRNA strand for the prevention of mpox and pre-clinical studies, and is expected to be a market competitive vaccine - co
** YTD, stock up 5.6%, Hang Seng Biotech Index .HSBIO up 11.4%
(Reporting by Donny Kwok)
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines